Skip to content

Pacira BioSciences, Inc.

PCRX· NasdaqCore metricsCIK 1396814

Pharmaceutical preparations553 peers

Last sale
Nov 12, 2026 · +0.01%
Market cap
$1.46B
40.09M shares
Filings
1,034
$176.65M
Q3 2026+3.6% FY25 yoy
$28.52M
Q3 2026N/M FY25 yoy
$22.27M
Q3 2026N/M FY25 yoy
$125.53M
Q3 2026derived−23.5% FY25 yoy
$0.70
Q3 2026N/M FY25 yoy
$246.96M
Q3 2026−42.7% FY25 yoy
$1.46B
38.8×
2.0×
2.1×
11.56%
—

Twelve months to Sep 30, 2026 · derived

Price

$36.47+51.18%+$12.35past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$726.41MFY 2025
$726.41M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$726,411,000reported
FY 20242024-12-31$700,966,000reported
FY 20232023-12-31$674,978,000reported
FY 20222022-12-31$666,823,000reported
FY 20212021-12-31$541,533,000 revisedreported
FY 20202020-12-31$429,647,000 revisedreported
FY 20192019-12-31$418,926,000reported
FY 20182018-12-31$332,427,000reported
FY 20172017-12-31$284,342,000 revisedreported
FY 20162016-12-31$270,073,000 revisedreported
FY 20152015-12-31$248,997,000reported
FY 20142014-12-31$197,668,000reported

Capital returns

Dividends and buybacks · FY2010 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$148.33M$148.33M—40.49M sh−12.5%108.5%
FY2024—$25.00M$25.00M—46.28M sh−0.5%14.0%
FY2023—$0.00$0.00—46.50M sh+1.2%0.0%
FY2022—$0.00$0.00—45.95M sh+2.5%0.0%
FY2010—$2.00K$2.00K—574.03K sh——

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018FY2019EXPAREL · FY2019 · $407.88MBupivacaine liposome injectable suspension · FY2019 · $3.15Miovera° · FY2019 · $7.90MFY2020EXPAREL · FY2020 · $413.34Miovera° · FY2020 · $8.82MBupivacaine liposome injectable suspension · FY2020 · $4.46MRoyalty revenue · FY2020 · $3.03Miovera° · FY2020 · $8.82MFY2021EXPAREL · FY2021 · $506.52MZILRETTA · FY2021 · $12.68Miovera° · FY2021 · $16.16MBupivacaine liposome injectable suspension · FY2021 · $3.61MRoyalty revenue · FY2021 · $2.44MCollaborative licensing and milestone revenue · FY2021 · $125.00Kiovera° · FY2021 · $16.16MFY2022EXPAREL · FY2022 · $536.90MZILRETTA · FY2022 · $105.52Miovera° · FY2022 · $15.26MBupivacaine liposome injectable suspension · FY2022 · $6.48MRoyalty revenue · FY2022 · $2.67MFY2023EXPAREL · FY2023 · $538.12MZILRETTA · FY2023 · $111.10Miovera° · FY2023 · $19.69MBupivacaine liposome injectable suspension · FY2023 · $3.34MRoyalty revenue · FY2023 · $2.73MFY2024EXPAREL · FY2024 · $548.96MZILRETTA · FY2024 · $118.09Miovera° · FY2024 · $22.81MBupivacaine liposome injectable suspension · FY2024 · $7.32MRoyalty revenue · FY2024 · $3.78MFY2025EXPAREL · FY2025 · $575.13MZILRETTA · FY2025 · $116.63Miovera° · FY2025 · $24.18MBupivacaine liposome injectable suspension · FY2025 · $6.91MRoyalty revenue · FY2025 · $3.56M
LineFY2025ShareChange
EXPAREL$575.13M79%+4.8%
ZILRETTA$116.63M16%−1.2%
iovera°$24.18M3.3%+6.0%
Bupivacaine liposome injectable suspension$6.91M1.0%−5.6%
Royalty revenue$3.56M0.5%−5.9%
Collaborative licensing and milestone revenue———
iovera°———
Total$726.41M

From the 10-K filed Feb 26, 2026PCRX

Pharmaceutical preparations

Pacira BioSciences, Inc. is the 44th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR